Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid

Journal of Proteome Research

Volumn 11, Issue 10, 2012, Pages 5034-5045

  Whelan, Stephen A ^a,b   He, Jianbo ^b   Lu, Ming ^b   Souda, Puneet ^b   Saxton, Romaine E ^c   Faull, Kym F ^b   Whitelegge, Julian P ^b   Chang, Helena R ^b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarkers; blood assay; breast cancer; HER2; mass spectrometry; proteomics; proximal fluid; single nucleotide polymorphism (SNP); triple negative

Indexed keywords

AGRIN; ALANINE; ALPHA ACTININ 4; BETA TUBULIN; BIOLOGICAL MARKER; CATHEPSIN D; CLUSTERIN; COFILIN 1; ELONGATION FACTOR 2; ENOLASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FRUCTOSE BISPHOSPHATE ALDOLASE; GALECTIN 3; GLUCOSE 6 PHOSPHATE ISOMERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HERMES ANTIGEN; HISTONE H2B; NUCLEOSIDE DIPHOSPHATE KINASE; PEROXIREDOXIN 1; PROGESTERONE RECEPTOR; PROTEOME; SOMATOMEDIN BINDING PROTEIN 2; THROMBOSPONDIN 1; TRANSCORTIN; UNCLASSIFIED DRUG; VALINE; VIMENTIN; ZINC ALPHA2 GLYCOPROTEIN;

AMINO ACID SUBSTITUTION; ANALYTIC METHOD; ARTICLE; BODY FLUID; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; FRACTIONATION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; TRIPLE NEGATIVE BREAST CANCER; UNINDEXED SEQUENCE; VALIDATION PROCESS; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CATHEPSIN D; CHROMATOGRAPHY, LIQUID; CULTURE MEDIA, CONDITIONED; FEMALE; FRUCTOSE-BISPHOSPHATE ALDOLASE; HUMANS; KERATIN-19; MCF-7 CELLS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; PROTEOME; PROTEOMICS; RECEPTOR, ERBB-2; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84867449270     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300606e     Document Type: Article

References (52)

1. Etzioni, R.; Urban, N.; Ramsey, S.; McIntosh, M.; Schwartz, S.; Reid, B.; Radich, J.; Anderson, G.; Hartwell, L. The case for early detection Nat. Rev. 2003, 3 (4) 243-52
2. Pan, S.; Aebersold, R.; Chen, R.; Rush, J.; Goodlett, D. R.; McIntosh, M. W.; Zhang, J.; Brentnall, T. A. Mass spectrometry based targeted protein quantification: methods and applications J. Proteome Res. 2009, 8 (2) 787-97
3. Armstrong, K.; Moye, E.; Williams, S.; Berlin, J. A.; Reynolds, E. E. Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians Ann. Intern. Med. 2007, 146 (7) 516-26
4. Glick, S. J.; Breast, C. T. Annu. Rev. Biomed. Eng. 2006, not supplied.
5. Karellas, A.; Vedantham, S. Breast cancer imaging: a perspective for the next decade Med. Phys. 2008, 35 (11) 4878-97
6. Peppercorn, J. Breast cancer in women under 40 Oncology 2009, 23 (6) 465-74
7. Houssami, N.; Irwig, L.; Simpson, J. M.; McKessar, M.; Blome, S.; Noakes, J. The influence of knowledge of mammography findings on the accuracy of breast ultrasound in symptomatic women Breast J. 2005, 11 (3) 167-72
8. Arslan, A. A.; Formenti, S. C. Mammography in developing countries: the risks associated with globalizing the experiences of the Western world Nat. Clin. Prac. 2009, 6 (3) 136-7
9. Jorgensen, K. J.; Gotzsche, P. C. Who evaluates public health programmes? A review of the NHS Breast Screening Programme J. R. Soc. Med. 2012, 103 (1) 14-20
10. Gotzsche, P. C.; Nielsen, M. Screening for breast cancer with mammography Cochrane Database Syst. Rev. (Online) 2009, 4) CD001877
11. Kohn, E. C.; Azad, N.; Annunziata, C.; Dhamoon, A. S.; Whiteley, G. Proteomics as a tool for biomarker discovery Dis. Markers 2007, 23 (5-6) 411-7
12. Diamandis, E. P. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 2003, 49 (8) 1272-5
13. Rifai, N.; Gillette, M. A.; Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility Nat. Biotechnol. 2006, 24 (8) 971-83
14. Diamandis, E. P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations Mol. Cell. Proteomics 2004, 3 (4) 367-78
15. Kulasingam, V.; Diamandis, E. P. Proteomic analysis of conditioned media from three breast cancer cell lines: A mine for biomarkers and therapeutic targets. Mol. Cell. Proteomics 2007, not supplied.
16. Bast, R. C., Jr.; Ravdin, P.; Hayes, D. F.; Bates, S.; Fritsche, H., Jr.; Jessup, J. M.; Kemeny, N.; Locker, G. Y.; Mennel, R. G.; Somerfield, M. R. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J. Clin. Oncol. 2001, 19 (6) 1865-78
17. Dhanasekaran, S. M.; Barrette, T. R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K. J.; Rubin, M. A.; Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer Nature 2001, 412 (6849) 822-6
18. Mathelin, C.; Koehl, C.; Rio, M. C. [Circulating proteinic biomarkers and breast cancer] Gynecol., Obstet. Fertil. 2006, 34 (7-8) 638-46
19. Lauro, S.; Trasatti, L.; Bordin, F.; Lanzetta, G.; Bria, E.; Gelibter, A.; Reale, M. G.; Vecchione, A. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients Anticancer Res. 1999, 19 (4C) 3511-5
20. Ludwig, J. A.; Weinstein, J. N. Biomarkers in cancer staging, prognosis and treatment selection Nat. Rev. 2005, 5 (11) 845-56
21. Yates, J. R.; Ruse, C. I.; Nakorchevsky, A. Proteomics by mass spectrometry: approaches, advances, and applications Annu. Rev. Biomed. Eng. 2009, 11, 49-79
22. Perry, R. H.; Cooks, R. G.; Noll, R. J. Orbitrap mass spectrometry: instrumentation, ion motion and applications Mass Spectrom. Rev. 2008, 27 (6) 661-99
23. Michalski, A.; Damoc, E.; Hauschild, J. P.; Lange, O.; Wieghaus, A.; Makarov, A.; Nagaraj, N.; Cox, J.; Mann, M.; Horning, S. Mass spectrometry-based proteomics using Q Exactive, a high-performance benchtop quadrupole Orbitrap mass spectrometer Mol. Cell. Proteomics 2011, 10 (9) M111 011015
24. Irvin, W. J., Jr.; Carey, L. A. What is triple-negative breast cancer? Eur. J. Cancer 2008, 44 (18) 2799-805
25. Bedard, P. L.; de Azambuja, E.; Cardoso, F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer Curr. Cancer Drug Targets 2009, 9 (2) 148-62
26. Colleoni, M.; Zahrieh, D.; Gelber, R. D.; Viale, G.; Luini, A.; Veronesi, P.; Intra, M.; Galimberti, V.; Renne, G.; Goldhirsch, A. Preoperative systemic treatment: prediction of responsiveness Breast (Edinburgh, Scotland) 2003, 12 (6) 538-42
27. Cleator, S.; Heller, W.; Coombes, R. C. Triple-negative breast cancer: therapeutic options Lancet Oncol. 2007, 8 (3) 235-44
28. Duffy, M. J. Serum tumor markers in breast cancer: are they of clinical value? Clin. Chem. 2006, 52 (3) 345-51
29. Al-azawi, D.; Kelly, G.; Myers, E.; McDermott, E. W.; Hill, A. D.; Duffy, M. J.; Higgins, N. O. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer BMC Cancer 2006, 6, 220
30. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; Hayes, D. F.; Bast, R. C., Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J. Clin. Oncol. 2007, 25 (33) 5287-312
31. Charafe-Jauffret, E.; Ginestier, C.; Monville, F.; Finetti, P.; Adelaide, J.; Cervera, N.; Fekairi, S.; Xerri, L.; Jacquemier, J.; Birnbaum, D.; Bertucci, F. Gene expression profiling of breast cell lines identifies potential new basal markers Oncogene 2006, 25 (15) 2273-84
32. Whelan, S. A.; Lu, M.; He, J.; Yan, W.; Saxton, R. E.; Faull, K. F.; Whitelegge, J. P.; Chang, H. R. Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers J. Proteome Res. 2009, 8 (8) 4151-60
33. Lu, M.; Whitelegge, J. P.; Whelan, S. A.; He, J.; Saxton, R. E.; Faull, K. F.; Chang, H. R. Hydrophobic Fractionation Enhances Novel Protein Detection by Mass Spectrometry in Triple Negative Breast Cancer J. Proteomics Bioinform. 2010, 3, 029-038
34. Craig, R.; Beavis, R. C. A method for reducing the time required to match protein sequences with tandem mass spectra Rapid Commun. Mass Spectrom. 2003, 17 (20) 2310-6
35. Nesvizhskii, A. I.; Keller, A.; Kolker, E.; Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry Anal. Chem. 2003, 75 (17) 4646-58
36. Papassotiropoulos, A.; Bagli, M.; Kurz, A.; Kornhuber, J.; Forstl, H.; Maier, W.; Pauls, J.; Lautenschlager, N.; Heun, R. A genetic variation of cathepsin D is a major risk factor for Alzheimers disease Ann. Neurol. 2000, 47 (3) 399-403
37. Steinfeld, R.; Reinhardt, K.; Schreiber, K.; Hillebrand, M.; Kraetzner, R.; Bruck, W.; Saftig, P.; Gartner, J. Cathepsin D deficiency is associated with a human neurodegenerative disorder Am. J. Hum. Genet. 2006, 78 (6) 988-98
38. Lu, M.; Whelan, S. A.; He, J.; Saxton, R. E.; Faull, K. F.; Whitelegge, J. P.; Chang, H. R. Hydrophobic Pr.oteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer Clin. Proteomics 2010, 6 (3) 93-103
39. He, J.; Whelan, S. A.; Lu, M.; Shen, D.; Chung, D. U.; Saxton, R. E.; Faull, K. F.; Whitelegge, J. P.; Chang, H. R. Mass spectrometry identified protein biosignatures for classifying breast cancer and predicting responses to chemotherapy. Breast Cancer Res. 2010, not supplied.
40. LaFramboise, T. Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances Nucleic Acids Res. 2009, 37 (13) 4181-93
41. Touitou, I.; Capony, F.; Brouillet, J. P.; Rochefort, H. Missense polymorphism (C/T224) in the human cathepsin D pro-fragment determined by polymerase chain reaction - single strand conformational polymorphism analysis and possible consequences in cancer cells Eur. J. Cancer 1994, 30A (3) 390-4
42. Benes, P.; Vetvicka, V.; Fusek, M. Cathepsin D - many functions of one aspartic protease Crit. Rev. Oncol./Hematol. 2008, 68 (1) 12-28
43. Baeckstrom, D.; Hansson, G. C.; Nilsson, O.; Johansson, C.; Gendler, S. J.; Lindholm, L. Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins J. Biol. Chem. 1991, 266 (32) 21537-47
44. Schmitz, B.; Peter-Katalinic, J.; Egge, H.; Schachner, M. Monoclonal antibodies raised against membrane glycoproteins from mouse brain recognize N-linked oligomannosidic glycans Glycobiology 1993, 3 (6) 609-17
45. Slawson, C.; Lakshmanan, T.; Knapp, S.; Hart, G. W. A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin Mol. Biol. Cell 2008, 19 (10) 4130-40
46. Cui, Y.; Tian, M.; Zong, M.; Teng, M.; Chen, Y.; Lu, J.; Jiang, J.; Liu, X.; Han, J. Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma Pancreatology 2009, 9 (1-2) 89-98
47. Suzuki, A.; Iizuka, A.; Komiyama, M.; Takikawa, M.; Kume, A.; Tai, S.; Ohshita, C.; Kurusu, A.; Nakamura, Y.; Yamamoto, A.; Yamazaki, N.; Yoshikawa, S.; Kiyohara, Y.; Akiyama, Y. Identification of melanoma antigens using a Serological Proteome Approach (SERPA) Cancer Genomics Proteomics 2012, 7 (1) 17-23
48. Gomez, A.; Ferrer, I. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases J. Neurosci. Res. 2009, 87 (4) 1002-13
49. Ibsen, K. H.; Orlando, R. A.; Garratt, K. N.; Hernandez, A. M.; Giorlando, S.; Nungaray, G. Expression of multimolecular forms of pyruvate kinase in normal, benign, and malignant human breast tissue Cancer Res. 1982, 42 (3) 888-92
50. Chen, Y.; Zou, T. N.; Wu, Z. P.; Zhou, Y. C.; Gu, Y. L.; Liu, X.; Jin, C. G.; Wang, X. C. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer Int. J. Biol. Markers 2012, 25 (2) 59-68
51. Ignatiadis, M.; Georgoulias, V.; Mavroudis, D. Circulating tumor cells in breast cancer Curr. Opin. Obstet. Gynecol. 2008, 20 (1) 55-60
52. Bonin, S.; Brunetti, D.; Benedetti, E.; Dotti, I.; Gorji, N.; Stanta, G. Molecular characterisation of breast cancer patients at high and low recurrence risk Virchows Arch. 2008, 452 (3) 241-50